Promising Phase 2 Results for Novel Oral Alzheimer ' s Drug Promising Phase 2 Results for Novel Oral Alzheimer ' s Drug

An investigational dual PPAR agonist modifies Alzheimer ' s pathology and shows cognitive benefit in adults with mild-to-moderate disease and high plasma pTau-217 ratio, early data show.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Psychiatry News Source Type: news